8-K current report · filed Sep 10, 2026

STAAR SURGICAL CO (STAA) 8-K Current Report: September 10, 2026

Item 7.01Item EX-99.1Item 5.02STAA overview

Short answer

STAAR SURGICAL CO (STAA) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers). David Bailey appointed Chief Commercial Officer effective September 8, 2026, returning after prior CEO and international leadership roles.

STAAR SURGICAL CO 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • David Bailey appointed Chief Commercial Officer effective September 8, 2026, returning after prior CEO and international leadership roles
  • Base salary CHF 462,825, approximately $575,000, plus 2026 target bonus equal to 60% of base salary
  • Initial $850,000 RSU grant vesting evenly over three years, supporting retention through 2029
  • Additional $1,400,000 2026 long-term incentive award, split 50% stock options and 50% RSUs, prorated for start date
  • Appointment strengthens commercial leadership and market-expansion execution, with compensation creating meaningful shareholder dilution and retention costs

Item 7.01 · Regulation FD Disclosure

  • Bailey appointed Chief Commercial Officer, adding dedicated leadership for commercial strategy
  • Executive change may influence sales execution, market expansion, and revenue growth priorities
  • Press release furnished as Exhibit 99.1 for appointment details and background

Item EX-99.1 · Exhibit EX-99.1

  • Former CEO David Bailey appointed Chief Commercial Officer, rejoining executive committee and reporting to CEO Warren Foust
  • Mandate centered on accelerating revenue growth and expanding EVO ICL adoption as laser refractive volumes decline globally
  • Bailey’s prior tenure included ICL commercialization across Asia, 2005 FDA approval, and Canon Japan joint-venture acquisition
  • Historical international revenues reached 74% of total by 2011, while ICL revenue grew to approximately $32 million
  • Management highlights expansion opportunities across China, Japan, U.S., South and Southeast Asia, South America, and Africa

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STAAR SURGICAL CO 8-K filings

Get the next STAA 8-K as it lands

Follow STAA for push alerts, or ask the research agent what this filing means.